ASH 2023 – Ramón García-Sanz
Ramón García-Sanz gives insights into the assessment of residual disease in multiple myeloma and explains future clinical implications of these data. Moreover, he discusses in which ways the evaluation of minimal residual disease might improve the management of patients with Waldenström macroglobulinemia and shares his personal highlight from the ASH 2023 congress.
Here is the full ASH 2023 report.
More posts
Exploring chemotherapy-free approaches in the treatment of DLBCL
Exploring chemotherapy-free approaches in the treatment of DLBCL Smart Stop: qu
Updated findings in CLL with a focus on BTK- and Bcl-2–targeted therapies
Updated findings in CLL with a focus on BTK- and Bcl-2–targeted therapies Treat
Follicular lymphoma: BTK inhibition and bispecific antibodies
Follicular lymphoma: BTK inhibition and bispecific antibodies Acalabrutinib in
Improving responses in multiple myeloma
Improving responses in multiple myeloma PERSEUS: D-VRd vs. VRd An established t
Waldenström macroglobulinemia: optimizing outcomes in the first and later lines
Waldenström macroglobulinemia: optimizing outcomes in the first and later lines
Mantle cell lymphoma: emerging treatment regimens and new standards
Mantle cell lymphoma: emerging treatment regimens and new standards SYMPATICO:
